Effect Of GuJin Xiaoji Decoction On The Efficacy And Immune Function Of Patients Treated With Chemotherapy For Stage ⅢB-Ⅳ Lung Adenocarcinoma

Objective:To compare the efficacy of pemetrexed +cisplatin/carboplatin(AP/AC regimen)combined with Gu Jin Xiaoji Decoction on patients with stage IIIb-IV lung adenocarcinoma,the improvement of quality of life and the effect on T-lymphocyte subsets and cytokines in peripheral blood.To explore the value of Gu Jin Xiaoji Decoction in the treatment of IIIb-IV-stage lung adenocarcinoma.Method:In this study,60 patients with stage IIIb-IV lung adenocarcinoma who met the inclusion and exclusion criteria and were located in the Department of Oncology of Qingdao Traditional Chinese Medicine Hospital from November 01,2021 to November 01,2022 were selected and divided into a control group and an observation group using the random number table method.30 cases in the control group and 30 cases in the observation group,the ratio of the control group to the observation group was 1: 1.The AP regimen was applied to the control group and the treatment group was treated with The control group was treated with the AP regimen,and the treatment group was treated with Gu Jin Xiaoji Decoction on top of the control group.Chemotherapy was administered once every 3 weeks for one cycle,for a total of 2 cycles of6 weeks.After 6 weeks of treatment,the efficacy was assessed in terms of TCM evidence score,KPS score,LCSS score,immune function,cytokines,tumour markers and safety indicators.Result:We compared characteristics such as age,gender,KPS(Karlsberg Functional Status Score)score and clinical stage between the two groups and all baseline characteristics were not statistically different between the two groups(p> 0.05)and were comparable for a randomised controlled trial.The results found that: 1.Chinese medicine symptom scores: the Chinese medicine symptom scores in the treatment group were significantly lower than before,while there was no improvement in the control group,and the improvement rate of the symptoms in the treatment group was higher than that in the control group.2.KPS scores: Patients in the treatment group showed an improvement in their scores compared to the pre-treatment scores,with a statistically significant difference,while there was no significant difference in the control group.3.Lung Cancer Symptom Scale(LCSS):Patients in the treatment group had lower scores and relief of clinical symptoms relative to pre-treatment,while the control group had worse symptoms and higher scores after treatment.4.Immune function:There was no significant difference in the absolute values of total T lymph subpopulation(CD3+),helper T cells(CD4+),suppressor T lymphocytes(CD8+),natural killer cells(NK),and CD4+/CD8+ between the two groups before treatment.After treatment,the absolute values of CD3+,CD4+,NK and CD4+/CD8+ in the treatment group were higher than before treatment,and the difference was statistically significant,while the rest of the indicators were not significantly different from before.In contrast,the absolute values of CD3+,CD4+,CD8+ cells and CD4+/CD8+ in the control group decreased compared with those before treatment,and the difference was statistically significant,and no significant change was seen in the absolute value of NK compared with that before treatment.Comparing the indices of CD3+,CD4+,CD4+/CD8+ and NK between the two groups before and after treatment,it was found that the difference in total score was higher in the treatment group compared to the control group,and the difference was statistically significant.5.Cytokines: The levels of interleukin 2(IL-2),interleukin 8(IL-8),tumour necrosis factor-α(TNF-α),interferon-α(IFN-α)and interferon-γ(IFN-γ)were not significantly different between the two groups before treatment.After treatment,the levels of IL-2,IFN-α and IFN-γ were higher in the treatment group than before treatment,and the differences were statistically significant;the mean levels of TNF-α were lower than before treatment,but the differences were not statistically significant;the levels of IL-8 were not significantly different from those before treatment.In contrast,the levels of IL-2,IL-8,TNF-α,IFN-α and IFN-γ levels in the control group were not significantly different from those before treatment;comparing the levels of IL-2,TNF-α,IFN-α and IFN-γ in the two groups after treatment,it was found that the difference was higher in the treatment group compared to the control group,and the difference was statistically significant.6.Tumour markers:Before treatment,there were no significant differences in the values of glycoconjugate antigen 125(CA125),carcinoembryonic antigen(CEA)and cytokeratin 19 fragment(CYFRA21-1)between the two groups for comparison.After treatment,CA125 and CEA values in the treatment group were lower than before treatment,with statistically significant differences,and no significant differences were seen in CYFRA21-1 levels compared to before.No significant differences in CA125,CEA and CYFRA21-1 values were seen in the control group compared to before treatment.Comparing the two groups of CA125 and CEA,the difference was higher in the treatment group than in the control group and the difference was statistically significant.7.Safety indicators: No significant differences were found in the white blood cells,red blood cells,platelets,ghrelin,glutamic aminotransferase,glutamic oxalacetic aminotransferase,creatinine and urea nitrogen between the two groups.No remaining serious adverse reactions occurred during treatment in both groups.Conclusion :Combined with chemotherapy,Gu Jin Xiaoji Decoction can effectively enhance the immune function,improve the therapeutic effect,relieve clinical symptoms and improve the quality of life.